DSpace Repository

FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?

Show simple item record

dc.contributor.author Gaikwad, Anil Bhanudas
dc.date.accessioned 2023-12-21T04:40:02Z
dc.date.available 2023-12-21T04:40:02Z
dc.date.issued 2016
dc.identifier.uri https://www.ingentaconnect.com/content/ben/cdr/2016/00000012/00000003/art00007
dc.identifier.uri http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13477
dc.description.abstract FoxO1, one of the most widely expressed sub-families of the winged helix forkhead factors, is biologically ‘omni-functional’ owing to its far-flung roles in metabolism, cell cycle, tissue differentiation and development and oxidative stress response. The knowledge of involvement of FoxO1 in metabolic disorders has long been there, but the potential target remained underutilized due to unavailability of specific and potent inhibitors. The review provides an insight into the role of FoxO1 in orchestrating metabolic diseases’ pathogenesis (including diabetes, its secondary complications and obesity) and compiles the literature on FoxO1 inhibitors. The emergence of various natural molecules and synthesized small molecules like AS1842856 as FoxO1 inhibitors urges us to think further and decide the future course of drug development for the management of metabolic disorders. en_US
dc.language.iso en en_US
dc.publisher Bentham Science en_US
dc.subject Pharmacy en_US
dc.subject AS1842856 en_US
dc.subject FoxO1 en_US
dc.subject Metabolic disorders en_US
dc.subject Obesity en_US
dc.subject Diabetic complications en_US
dc.title FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders? en_US
dc.type Article en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account